Loading page…

Report overview

The report records consolidated revenue of HUF 805,158m in 2023, while pharmaceutical segment turnover rose 13.9%. It highlights growth in women's healthcare and neuropsychiatry, including increased sales of products such as Ryeqo and Drovelis and higher VRAYLAR royalty income. The report also states that Group-level GHG emissions declined 2% and that the company is embracing the challenge of becoming a net-zero company by 2050.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 8 March 2024
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

Other

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board
Net zero target

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services